DR.REDDY'S LABORATORIES LTD. - 500124 - Announcement under Regulation 30 (LODR)-Newspaper Publication
Copies of newspaper publication - Loss of share certificates12-04-2024
12-04-2024
Dr. Reddy's launches migraine management wearable device, Nerivio, in Germany
The device is approved by the USFDA and has CE-mark certification in Europe.10-04-2024
DR.REDDY'S LABORATORIES LTD. - 500124 - Compliance Certificate For The Period Ended March 31, 2024
Compliance certificate for the period ended March 31, 202408-04-2024
Dr. Reddy's,Bayer ink pact for second brand ofVericiguat
Under the terms of this agreement, Bayer has granted non-exclusive rights to Hyderabad-based Dr. Reddy's under the brand name Gantra05-04-2024
DR.REDDY'S LABORATORIES LTD. - 500124 - Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
Certificate under Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 201803-04-2024
Buy Dr Reddy's Laboratories; target of Rs 6537: Sharekhan
Sharekhan is bullish on Dr Reddy's Laboratories has recommended buy rating on the stock with a target price of Rs 6537 in its research report dated April 01, 2024.02-04-2024
DR.REDDY'S LABORATORIES LTD. - 500124 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Issue of Letter of Confirmation in lieu of share certificate(s) reported lost/misplaced30-03-2024
Dr Reddy's gains on distribution tie-up with Sanofi Healthcare
Dr Reddy's Laboratories | A meeting of the board of directors of the company will be held on Tuesday, May 7, 2024, to consider and approve the audited standalone and consolidated financial results of the company.28-03-2024